TiGenix secures EUR 10 million in financing from Kreos Capital

Company ends year in strong position to fully leverage leading cell therapy platform

Leuven (BELGIUM) - December 23, 2013 - TiGenix (Euronext Brussels: TIG) announced today that it has signed a structured debt financing agreement of up to EUR 10 million with Kreos Capital (Kreos), Europe's largest and leading provider of growth debt to high-growth companies

The funds will supplement the EUR 12 million in equity financing TiGenix recently secured from Gri-Cel SA, and will be used for general growth purposes as TiGenix advances the development of its expanding pipeline of cell therapy products.

"In combination with the recent strategic investment by Gri-Cel/Grifols this funding significantly strengthens our financial position and allows us to aggressively expand our pipeline of proprietary cell therapy products,"said Eduardo Bravo, CEO of TiGenix."Importantly, it enables us to independently finalize the Phase III trial with our lead product Cx601 and file for European registration, and thus capture significantly more value from a potential partnering agreement. The addition of debt financing represents an attractive and, except for a limited warrant component, non-dilutive complement to our existing capital structure. We are delighted to finish the year with a solid balance sheet and additional resources to optimally leverage our world-leading cell therapy technology platform as we move forward."

"Kreos is very pleased to be able to support TiGenix as it further builds its strong cell therapy portfolio,"said Maurizio PetitBon, General Partner of Kreos."TiGenix constitutes one of our first investments in the public market, and we have been very impressed by the quality of the team, the technology platform and the underlying business."

About the loan agreement
Draw down:      three tranches at the Company's discretion: EUR 5 million in early February 2014; EUR 2.5 million by end of May, 2014; EUR 2.5 million by end of September, 2014
Term:                four years
Amortization:    starts at first anniversary
Interest:            12.5% fixed annual interest rate
Structure:          security over certain assets; no financial covenants
Warrants:         approximately 2 million warrants to be granted to Kreos, subject to shareholder approval; exercise price to equal 30-day average closing price of TiGenix share at date of issue of warrants; if shareholders do not approve the issue of warrants, Kreos is entitled to a payment of EUR 890,000 over 3 years

Suggested Articles

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.

The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.